mTOR and cancer: insights into a complex relationship

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216

Upstream and downstream of mTOR

Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181

TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival

Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083

mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery

Kim, D., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument‐Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 3,051

Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton

Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561

Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB

Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,097

Two TOR Complexes, Only One of which Is Rapamycin Sensitive, Have Distinct Roles in Cell Growth Control

Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886

Application of Meso Scale Technology for the Measurement of Phosphoproteins in Human Tumor Xenografts

Gowan, S. M., Hardcastle, A., Hallsworth, A., Valenti, M. R., Hunter, L.-J. K., Brandon, A. K. D. H., Garrett, M. D., Raynaud, F. I., Workman, P., Aherne, W., et al. (2007) · Assay and Drug Development Technologies · doi:10.1089/adt.2006.044 · Cited by 58

Systemic Therapies in Hepatocellular Carcinoma

Wörns, M., Weinmann, A., Schuchmann, M., & Galle, P. R. (2009) · Digestive Diseases · doi:10.1159/000218351 · Cited by 59

Threonine-120 Phosphorylation Regulated by Phosphoinositide-3-Kinase/Akt and Mammalian Target of Rapamycin Pathway Signaling Limits the Antitumor Activity of Mammalian Sterile 20-Like Kinase 1

Collak, F. K., Yagiz, K., Luthringer, D., Erkaya, B., & Cinar, B. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.358713 · Cited by 59

DNA-dependent protein kinase catalytic subunit (DNA-PKcs)-SIN1 association mediates ultraviolet B (UVB)-induced Akt Ser-473 phosphorylation and skin cell survival

Tu, Y., Ji, C., Yang, B., Yang, Z., Gu, H., Lu, C., Wang, R., Su, Z., Chen, B., Sun, W., et al. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-172 · Cited by 59

Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer

Musa, F., Alard, A., David‐West, G., Curtin, J. P., Blank, S. V., & Schneider, R. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0926 · Cited by 59

Novel application of metformin combined with targeted drugs on anticancer treatment

Deng, J., Peng, M., Wang, Z., Zhou, S., Xiao, D., Deng, J., Yang, X., Peng, J.-Y., & Yang, X. (2018) · Cancer Science · doi:10.1111/cas.13849 · Cited by 59

Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma

Santoni, M., Pantano, F., Amantini, C., Nabissi, M., Conti, A., Burattini, L., Zoccoli, A., Berardi, R., Santoni, G., Tonini, G., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.01.007 · Cited by 60

Inhibition of Polysome Assembly Enhances Imatinib Activity against Chronic Myelogenous Leukemia and Overcomes Imatinib Resistance

Zhang, M., Fu, W., Prabhu, S., Moore, J. C., Ko, J., Kim, J. W., Druker, B. J., Trapp, V., Fruehauf, J. P., Gram, H., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00477-08 · Cited by 59

PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy

Wander, S. A., Zhao, D., Besser, A. H., Hong, F., Wei, J., Ince, T. A., Milikowski, C., Bishopric, N. H., Minn, A. J., Creighton, C. J., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2389-6 · Cited by 58

Overexpression of Golgi phosphoprotein-3 (GOLPH3) in glioblastoma multiforme is associated with worse prognosis

Zhou, J., Xu, T., Qin, R., Yan, Y., Chen, C., Chen, Y., Yu, H., Xia, C., Lu, Y., Ding, X., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0970-9 · Cited by 58

Molecularly Targeted Therapies in Multiple Myeloma

de la Puente, P., Muz, B., Azab, F., Luderer, M. J., & Azab, A. K. (2014) · Leukemia Research and Treatment · doi:10.1155/2014/976567 · Cited by 60

Upregulation of glutamate transporter GLT-1 by mTOR-Akt-NF-кB cascade in astrocytic oxygen-glucose deprivation

Ji, Y.-F., Zhou, L., Xie, Y., Xu, S., Zhu, J., Teng, P., Shao, C., Wang, Y., Luo, J., & Shen, Y. (2013) · Glia · doi:10.1002/glia.22566 · Cited by 57

Mesenchymal stem cells-derived IL-6 activates AMPK/mTOR signaling to inhibit the proliferation of reactive astrocytes induced by hypoxic-ischemic brain damage

He, M., Shi, X., Yang, M., Yang, T., Li, T., & Chen, J. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.09.006 · Cited by 57

Suppression of Hypoxia-Inducible Factor 1α (HIF-1α) by Tirapazamine Is Dependent on eIF2α Phosphorylation Rather Than the mTORC1/4E-BP1 Pathway

Zhang, J., Cao, J., Weng, Q., Wu, R., Yan, Y., Jing, H., Zhu, H., He, Q., & Yang, B. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013910 · Cited by 56

The role of glucose metabolism and glucose-associated signalling in cancer.

Wittig, R., & Coy, J. F. (2008) · PubMed Central · Cited by 56

Functional Characterization of Glycine N-Methyltransferase and Its Interactive Protein DEPDC6/DEPTOR in Hepatocellular Carcinoma

Yen, C., Lu, Y.-C., Li, C., Lee, C.-M., Chen, C., Cheng, M.-Y., Huang, S.-F. K., Chen, K., Cheng, A., Liao, L.-Y., et al. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00331 · Cited by 56

Altered mTOR Signaling in Senescent Retinal Pigment Epithelium

Chen, Y., Wang, J., Cai, J., & Sternberg, P. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-5280 · Cited by 57

Mammalian target of rapamycin: Biological function and target for novel anticancer agents

Borders, E. B., Bivona, C. R., & Medina, P. J. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100020 · Cited by 56

Do airborne biogenic chemicals interact with the PI3K/Akt/mTOR cell signalling pathway to benefit human health and wellbeing in rural and coastal environments?

Moore, M. N. (2015) · Environmental Research · doi:10.1016/j.envres.2015.03.015 · Cited by 59

Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.

Billottet, C., Banerjee, L., Vanhaesebroeck, B., & Khwaja, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2608 · Cited by 61

Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel

Sessa, C., Tosi, D., Viganò, L., Albanell, J., Hess, D., Maur, M., Cresta, S., Locatelli, A., Angst, R., Rojo, F., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp504 · Cited by 56

m‐ TOR inhibitors and their potential role in haematological malignancies

Calimeri, T., & Ferreri, A. J. M. (2017) · British Journal of Haematology · doi:10.1111/bjh.14529 · Cited by 57

Inhibition of glycolysis enhances cisplatin-induced apoptosis in ovarian cancer cells

Loar, P., Wahl, H. N., Kshirsagar, M. P., Gossner, G., Griffith, K. A., & Liu, J. R. (2010) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2009.10.883 · Cited by 56

The Mammalian Target of Rapamycin Pathway as a Potential Target for Cancer Chemoprevention

Kopelovich, L., Fay, J. R., Sigman, C. C., & Crowell, J. A. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0045 · Cited by 54

Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo

Zhu, Y., Zhang, X., Liu, Y., Zhang, S., Liu, J., Ma, Y., & Zhang, J. (2012) · Tumor Biology · doi:10.1007/s13277-012-0383-6 · Cited by 55

Hyperactive mTOR and MNK1 phosphorylation of eIF4E confer tamoxifen resistance and estrogen independence through selective mRNA translation reprogrammingPreprint

Geter, P. A., Ernlund, A. W., Bakogianni, S., Alard, A., Arju, R., Giashuddin, S. M., Gadi, A., Bromberg, J., & Schneider, R. J. (2017) · Genes & Development · doi:10.1101/gad.305631.117 · Cited by 56

AMP-activated protein kinase (AMPK) as a potential therapeutic target independent of PI3K/Akt signaling in prostate cancer

Choudhury, Y., Yang, Z., Ahmad, I., Nixon, C., Salt, I. P., & Leung, H. Y. (2014) · Oncoscience · doi:10.18632/oncoscience.49 · Cited by 54

PTEN inhibition enhances neurite outgrowth in human embryonic stem cell–derived neuronal progenitor cells

Wyatt, L. A., Filbin, M. T., & Keirstead, H. S. (2014) · The Journal of Comparative Neurology · doi:10.1002/cne.23580 · Cited by 54

TRIENNIAL GROWTH SYMPOSIUM: Leucine acts as a nutrient signal to stimulate protein synthesis in neonatal pigs1,2

Suryawan, A., Orellana, R. A., Fiorotto, M. L., & Davis, T. A. (2010) · Journal of Animal Science · doi:10.2527/jas.2010-3400 · Cited by 55

Increasing longevity through caloric restriction or rapamycin feeding in mammals: common mechanisms for common outcomes?

Cox, L. S., & Mattison, J. A. (2009) · Aging Cell · doi:10.1111/j.1474-9726.2009.00509.x · Cited by 55

Ubiquitin Specific Protease 13 Regulates Tau Accumulation and Clearance in Models of Alzheimer’s Disease1

Liu, X., Hebron, M. L., Mulki, S., Wang, C., Lekah, E., Ferrante, D., Shi, W., Kurd-Misto, B. T., & Moussa, C. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190635 · Cited by 53

The mTOR Inhibitor Rapamycin Synergizes with a Fatty Acid Synthase Inhibitor to Induce Cytotoxicity in ER/HER2-Positive Breast Cancer Cells

Chen, Y., Wei, H., Minjuan, Z., Yan, X., Jingyue, Y., Liu, W., & Sheng, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097697 · Cited by 53

The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent

Li, C., Cui, J., Chen, M., Liu, C., Liu, F., Qian-de, Z., Zou, J., & Lu, P. (2015) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.972274 · Cited by 53

Targeting the Akt/mTOR pathway in Brca1-deficient cancers

Xiang, T., Jia, Y., Sherris, D., Li, S., Wang, H., Lu, D., & Yang, Q. (2011) · Oncogene · doi:10.1038/onc.2010.603 · Cited by 53

A phase I study of temsirolimus and metformin in advanced solid tumours

MacKenzie, M. J., Ernst, S., Johnson, C., & Winquist, E. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9570-8 · Cited by 53

Alpha-melanocyte stimulating hormone protects retinal pigment epithelium cells from oxidative stress through activation of melanocortin 1 receptor–Akt–mTOR signaling

Cheng, L., Cheng, L., Bi, H.-E., Zhang, Z.-Q., Yao, J., Zhou, X., & Jiang, Q. L. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.11.113 · Cited by 53

Current and future directions in mammalian target of rapamycin inhibitors development

Fasolo, A., & Sessa, C. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.541154 · Cited by 57

A Conserved Role of IQGAP1 in Regulating TOR Complex 1

Tekletsadik, Y. K., Sonn, R., & Osman, M. A. (2012) · Journal of Cell Science · doi:10.1242/jcs.098947 · Cited by 56

Pulmonary lymphangioleiomyomatosis (LAM): Progress and current challenges

Goncharova, E. A., & Krymskaya, V. P. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21419 · Cited by 53

Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy

Dowling, R. J. O., Pollak, M., & Sonenberg, N. (2009) · BioDrugs · doi:10.2165/00063030-200923020-00002 · Cited by 52

Targeted therapy of cancer stem cells: inhibition of mTOR in pre-clinical and clinical research

Son, B., Lee, W., Kim, H., Shin, H., & Park, H. H. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07077-8 · Cited by 55

A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase–regulated mammalian target of rapamycin activation

Gupta, M., Dillon, S. R., Ziesmer, S. C., Feldman, A. L., Witzig, T. E., Ansell, S. M., Cerhan, J. R., & Novak, A. J. (2009) · Blood · doi:10.1182/blood-2008-09-179762 · Cited by 54

BNIP3 is essential for mediating 6-thioguanine- and 5-fluorouracil-induced autophagy following DNA mismatch repair processing

Zeng, X., & Kinsella, T. J. (2010) · Cell Research · doi:10.1038/cr.2010.40 · Cited by 52

Rapamycin induces transactivation of the EGFR and increases cell survival

Chaturvedi, D., Gao, X., Cohen, M. S., Taunton, J., & Patel, T. B. (2009) · Oncogene · doi:10.1038/onc.2008.490 · Cited by 52

Suppression of mTOR via Akt-dependent and -independent mechanisms in selenium-treated colon cancer cells: involvement of AMPK 1

Lee, Y.-K., Park, S. Y., Kim, Y.-M., Kim, D. C., Lee, W. S., Surh, Y., & Park, O. J. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq040 · Cited by 51

Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma

Kaira, K., Serizawa, M., Koh, Y., Takahashi, T., Hanaoka, H., Oriuchi, N., Endo, M., Kondo, H., Nakajima, T., & Yamamoto, N. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.01.016 · Cited by 52

Pyrogallol, an absorbable microbial gallotannins-metabolite and mango polyphenols (Mangifera Indica L.) suppress breast cancer ductal carcinoma in situ proliferation in vitro

Nemec, M. J., Kim, H., Marciante, A. B., Barnes, R. C., Talcott, S. T., & Mertens‐Talcott, S. U. (2016) · Food & Function · doi:10.1039/c6fo00636a · Cited by 52

Activating Autophagy as a Therapeutic Strategy for Parkinson’s Disease

Fowler, A. J., & Moussa, C. (2018) · CNS Drugs · doi:10.1007/s40263-018-0497-5 · Cited by 51

Introduction of Somatic Mutation in MED12 Induces Wnt4/β-Catenin and Disrupts Autophagy in Human Uterine Myometrial Cell

Andaloussi, A. E., Al-Hendy, A. A., Ismail, N., Boyer, T., & Halder, S. K. (2020) · Reproductive Sciences · doi:10.1007/s43032-019-00084-7 · Cited by 52

RNF167 activates mTORC1 and promotes tumorigenesis by targeting CASTOR1 for ubiquitination and degradation

Li, T., Wang, X., Ju, E., da Silva, S. R., Chen, L., Zhang, X., Wei, S., & Gao, S. (2021) · Nature Communications · doi:10.1038/s41467-021-21206-3 · Cited by 55

Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging

Leontieva, O. V., Paszkiewicz, G., & Blagosklonny, M. V. (2012) · Aging · doi:10.18632/aging.100528 · Cited by 52

A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas

Beauchamp, R. L., James, M. F., DeSouza, P., Wagh, V., Zhao, W., Jordan, J. T., Stemmer-Rachamimov, A. O., Plotkin, S. R., Gusella, J. F., Haggarty, S. J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4858 · Cited by 51

Deconstructing mTOR complexes in regulation of Glioblastoma Multiforme and its stem cells

Jhanwar‐Uniyal, M., Jeevan, D. S., Neil, J. A., Shannon, C. M., Albert, L., & Murali, R. (2012) · Advances in Biological Regulation · doi:10.1016/j.jbior.2012.10.001 · Cited by 51

GILZ inhibits the mTORC2/AKT pathway in BCR-ABL+ cells

Joha, S., Nugues, A.-L., Hétuin, D., Berthon, C., Dezitter, X., Dauphin, V., Mahon, F., Roche‐Lestienne, C., Preudhomme, C., Quesnel, B., et al. (2011) · Oncogene · doi:10.1038/onc.2011.328 · Cited by 51

The Combination of RAD001 and MK-2206 Exerts Synergistic Cytotoxic Effects against PTEN Mutant Gastric Cancer Cells: Involvement of MAPK-Dependent Autophagic, but Not Apoptotic Cell Death Pathway

Ji, D., Zhang, Z., Cheng, L., Chang, J., Wang, S., Zheng, B., Zheng, R., Sun, Z., Wang, C., Zhang, Z.-Q., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085116 · Cited by 51

Inhibiting kinases in malignant gliomas

Chi, A. S., & Wen, P. Y. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.4.473 · Cited by 51

Synergistic Activities of MET/RON Inhibitor BMS-777607 and mTOR Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Zeng, J.-Y., Sharma, S., Zhou, Y.-Q., Yao, H., Hu, X., Zhang, R., & Wang, M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0242 · Cited by 51

mTOR in Growth and Protection of Hypertrophying Myocardium

Balasubramanian, S., Johnston, R. K., Moschella, P., Mani, S. K., Tuxworth, W. J., & Kuppuswamy, D. (2009) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/187152509787047603 · Cited by 51

Insulin-Like Growth Factor Signaling as a Therapeutic Target in Pancreatic Cancer

Rieder, S., W. Michalski, C., Friess, H., & Kleeff, >. (2011) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152011795677454 · Cited by 50

Antitumor Activity and Induction of TP53-Dependent Apoptosis toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423

Kashiyama, T., Oda, K., Ikeda, Y., Shiose, Y., Hirota, Y., Inaba, K., Makii, C., Kurikawa, R., Miyasaka, A., Koso, T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087220 · Cited by 51

Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis

Zhang, C., Ryu, Y., Chen, T. Z., Hall, C. P., Webster, D. R., & Kang, M. H. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.10.022 · Cited by 50

Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review

Huang, Z., Wu, Y., Zhou, X. Y., Qian, J., Zhu, W., Shu, Y., & Liu, P. (2015) · Future Oncology · doi:10.2217/fon.15.70 · Cited by 50

mTOR: more targets of resveratrol?

Widlund, A. L., Baur, J. A., & Vang, O. (2013) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2013.11 · Cited by 51

Multi-functional, multicompartmental hyaluronan-binding protein 1 (HABP1/p32/gC1qR): implication in cancer progression and metastasis

Saha, P., & Datta, K. (2018) · Oncotarget · doi:10.18632/oncotarget.24082 · Cited by 46

Interaction of ABC Multidrug Transporters with Anticancer Protein Kinase Inhibitors: Substrates and/or Inhibitors?

Özvegy‐Laczka, C., Hegedüs, C., Szakács, G., & Sarkadi, B. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909788166565 · Cited by 50

Safety and Feasibility of Using Sorafenib in Recurrent Hepatocellular Carcinoma after Orthotopic Liver Transplantation

Kim, R. D., El‐Gazzaz, G., Tan, A., Elson, P. J., Byrne, M., Chang, Y. D., & Aucejo, F. (2010) · Oncology · doi:10.1159/000319548 · Cited by 49

Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities

Hubbard, P. A., Moody, C. L., & Murali, R. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00478 · Cited by 49

TORC2 mediates the heat stress response in Drosophila by promoting the formation of stress granules

Jevtov, I., Zacharogianni, M., van Oorschot, M. M., van Zadelhoff, G., Aguilera-Gomez, A., Vuillez, I., Braakman, I., Hafen, E., Stocker, H., & Rabouille, C. (2015) · Journal of Cell Science · doi:10.1242/jcs.168724 · Cited by 49

Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation

Walker, N., Belloli, E. A., Stuckey, L. J., Chan, K. M., Lin, J., Lynch, W. R., Chang, A. C., Mazzoni, S. M., Fingar, D. C., & Lama, V. N. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.672170 · Cited by 49

Long non-coding RNA-CRNDE: a novel regulator of tumor growth and angiogenesis in hepatoblastoma

Dong, R., Liu, X., Zhang, B., Liu, B.-H., Zheng, S., & Dong, K. (2017) · Oncotarget · doi:10.18632/oncotarget.14992 · Cited by 49

High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma

Wang, S., Hwang, E. E., Guha, R., O'Neill, A. F., Melong, N., Veinotte, C. J., Saur, A. C., Wuerthele, K., Shen, M., McKnight, C. G., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0375 · Cited by 50

The FBXW7-SHOC2-Raptor Axis Controls the Cross-Talks between the RAS-ERK and mTORC1 Signaling Pathways

Xie, C.-M., Tan, M., Lin, X.-T., Wu, D., Jiang, Y., Tan, Y., Li, H., Ma, Y., Xiong, X., & Sun, Y. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.052 · Cited by 49

Targeting the mTOR Pathway Using Deforolimus in Cancer Therapy

Mahalingam, D., Sankhala, K. K., Mita, A. C., Giles, F. J., & Mita, M. M. (2009) · Future Oncology · doi:10.2217/fon.09.9 · Cited by 48

Ribosomal protein mRNAs are translationally-regulated during human dendritic cells activation by LPS

Ceppi, M., Clavarino, G., Gatti, E., Schmidt, E. K., Gassart, A. D., Blankenship, D., Ogola, G., Banchereau, J., Chaussabel, D., & Pierre, P. (2009) · Immunome Research · doi:10.1186/1745-7580-5-5 · Cited by 49

Cyclic AMP Inhibits the Proliferation of Thyroid Carcinoma Cell Lines through Regulation of CDK4 Phosphorylation

Rocha, A. S., Paternot, S., Coulonval, K., Dumont, J. E., Soares, P., & Roger, P. P. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-06-0617 · Cited by 49

The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models

Zhu, Y., Zhou, X., Zhu, L., Yao, C., Fang, J., Zhou, F., Deng, X., & Zhang, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.10389 · Cited by 48

AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications

Vakana, E., & Platanias, L. C. (2011) · Oncotarget · doi:10.18632/oncotarget.413 · Cited by 47

Targeted Therapies for Malignant Glioma: Progress and Potential

Mercer, R. W., Tyler, M. A., Ulasov, I. V., & Lesniak, M. S. (2009) · BioDrugs · doi:10.2165/00063030-200923010-00003 · Cited by 39

Transient mTOR Inhibition Facilitates Continuous Growth of Liver Tumors by Modulating the Maintenance of CD133+ Cell Populations

Yang, Z., Zhang, L., Ma, A., Liu, L., Li, J., Gu, J., & Liu, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028405 · Cited by 50

Reassessment of the role of FKBP38 in the Rheb/mTORC1 pathway

Uhlenbrock, K., Weiwad, M., Wetzker, R., Fischer, G. S., Wittinghofer, A., & Rubio, I. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.02.015 · Cited by 47

Chemical Inhibitors and microRNAs (miRNA) Targeting the Mammalian Target of Rapamycin (mTOR) Pathway: Potential for Novel Anticancer Therapeutics

Alqurashi, N., Hashimi, S. M., & Wei, M. Q. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14023874 · Cited by 47

Mammalian Target of Rapamycin Is a Therapeutic Target for Murine Ovarian Endometrioid Adenocarcinomas with Dysregulated Wnt/β-Catenin and PTEN

Tanwar, P. S., Zhang, L., Kaneko-Tarui, T., Curley, M. D., Taketo, M. M., Rani, P., Roberts, D. J., & Teixeira, J. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020715 · Cited by 48

Oral rapamycin reduces tumour burden and vascularization in Lkb1+/− mice

Robinson, J. P., Lai, C. S. L., Martin, A., Nye, E. L., Tomlinson, I. P. M., & Silver, A. R. (2009) · The Journal of Pathology · doi:10.1002/path.2562 · Cited by 48

Ionizing radiation regulates the expression of AMP-activated protein kinase (AMPK) in epithelial cancer cells

Sanli, T., Storozhuk, Y., Linher‐Melville, K., Bristow, R. G., Laderoute, K. R., Viollet, B., Wright, J. R., Singh, G., & Tsakiridis, T. K. (2012) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.11.014 · Cited by 47

Perifosine sensitizes UVB-induced apoptosis in skin cells: New implication of skin cancer prevention?

Ji, C., Yang, Y., Yang, Z. P., Tu, Y., Cheng, L., Chen, B., Xia, J., Sun, W., Su, Z., He, L., et al. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.05.003 · Cited by 47

Targeting translation in acute myeloid leukemia: A new paradigm for therapy?

Tamburini, J., Green, A. S., Chapuis, N., Bardet, V., Lacombe, C., Mayeux, P., & Bouscary, D. (2009) · Cell Cycle · doi:10.4161/cc.8.23.10091 · Cited by 53

Discovering new mTOR inhibitors for cancer treatment through virtual screening methods and in vitro assays

Wang, L., Chen, L., Yu, M., Xu, L., Cheng, B. H., Lin, Y., Gu, Q., He, X., & Xu, J. (2016) · Scientific Reports · doi:10.1038/srep18987 · Cited by 47

Ammonia Induces Autophagy through Dopamine Receptor D3 and MTOR

Li, Z., Ji, X., Wang, W., Liu, J., Liang, X., Wu, H., Liu, J. L., Eggert, U., Liu, Q., & Zhang, X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153526 · Cited by 47

PTEN negatively regulates mTORC2 formation and signaling in grade IV glioma via Rictor hyperphosphorylation at Thr1135 and direct the mode of action of an mTORC1/2 inhibitor

Bhattacharya, K., Maiti, S., & Mandal, C. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.34 · Cited by 46

Eukaryotic Translation Initiation Factor 4 Gamma 1 (EIF4G1): a target for cancer therapeutic intervention?

Jaiswal, P. K., Koul, S., Palanisamy, N., & Koul, H. K. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0947-2 · Cited by 46

Amino acid sensing and mTOR regulation: inside or out?

Goberdhan, D. C. I., Ogmundsdottir, M. H., Kazi, S., Reynolds, B., Visvalingam, S. M., WILSON, C. G., & Boyd, C. A. R. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370248 · Cited by 47

CCL2 Is a Negative Regulator of AMP-Activated Protein Kinase to Sustain mTOR Complex-1 Activation, Survivin Expression, and Cell Survival in Human Prostate Cancer PC3 Cells

Roca, H., Varsos, Z. S., & Pienta, K. J. (2009) · Neoplasia · doi:10.1593/neo.09936 · Cited by 47

Deletion of Tuberous Sclerosis 1 in Somatic Cells of the Murine Reproductive Tract Causes Female Infertility

Tanaka, Y., Park, J. H., Tanwar, P. S., Kaneko-Tarui, T., Mittal, S., Lee, H., & Teixeira, J. M. (2011) · Endocrinology · doi:10.1210/en.2011-1191 · Cited by 46

Targeting the PI3K/mTOR Axis, Alone and in Combination with Autophagy Blockade, for the Treatment of Malignant Peripheral Nerve Sheath Tumors

Ghadimi, M. P., Lopez, G., Torres, K. E., Belousov, R., Young, E. D., Liu, J., Savannah, K. J. B., Hoffman, A., Lusby, K., Lazar, A. J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0015 · Cited by 46

A Retroinhibition Approach Reveals a Tumor Cell–Autonomous Response to Rapamycin in Head and Neck Cancer

Amornphimoltham, P., Patel, V., Leelahavanichkul, K., Abraham, R. T., & Gutkind, J. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1756 · Cited by 45

Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb®) in human breast carcinoma cells

Vázquez‐Martín, A., Oliveras‐Ferraros, C., Colomer, R., Brunet, J., & Menéndez, J. A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm589 · Cited by 46

Mutational inactivation of mTORC1 repressor gene DEPDC5 in human gastrointestinal stromal tumors

Pang, Y., Xie, F., Cao, H., Wang, C.-M., Zhu, M.-J., Liu, X., Lu, X., Huang, T., Shen, Y.-Y., Li, K., et al. (2019) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1914542116 · Cited by 36

Activation of mTOR in a subgroup of ovarian carcinomas: Correlation with p-eIF-4E and prognosis

Noske (1994) · Oncology Reports · doi:10.3892/or_00000160 · Cited by 46

Combined Inhibition of mTORC1 and mTORC2 Signaling Pathways Is a Promising Therapeutic Option in Inhibiting Pheochromocytoma Tumor Growth: In Vitro and In Vivo Studies in Female Athymic Nude Mice

Giubellino, A., Bullova, P., Nölting, S., Turková, H., Powers, J. F., Liu, Q., Guichard, S. M., Tischler, A. S., Grossman, A. B., & Pacák, K. (2013) · Endocrinology · doi:10.1210/en.2012-1854 · Cited by 50

Reprogramming of the MicroRNA Transcriptome Mediates Resistance to Rapamycin

Totary-Jain, H., Sanoudou, D., Ben‐Dov, I. Z., Dautriche, C. N., Guarnieri, P., Marx, S. O., Tuschl, T., & Marks, A. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.416446 · Cited by 45

Drug discovery targeting the mTOR pathway

Martelli, A. M., Buontempo, F., & McCubrey, J. A. (2018) · Clinical Science · doi:10.1042/cs20171158 · Cited by 77

TOR (target of rapamycin) as an anti-cancer target

Bousquet, G., Dreyer, C., Faivre, S. J., & Raymond, É. (2007) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2008.04.004 · Cited by 2

Mammalian Target of Rapamycin (mTOR) Signalling Pathway-A Potential Target for Cancer Intervention: A Short Overview

Basnet, R., Basnet, B. B., Gupta, R., Basnet, T. B., Khadka, S., & Alam, M. S. (2023) · Current Molecular Pharmacology · doi:10.2174/1874467217666230331081959 · Cited by 11

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

Wander, S. A., Hennessy, B. T., & Slingerland, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44145 · Cited by 427

Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies

Mehta, D., Rajput, K., Jain, D., Bajaj, A., & Dasgupta, U. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00530 · Cited by 25